Gabasync

Last updated

Gabasync is an ineffective treatment promoted for methamphetamine addiction, although it had also been claimed to be effective for dependence on alcohol or cocaine. [1] It was marketed as PROMETA. The treatment, based loosely on research of a Spanish psychologist, involved a combination of three medications (gabapentin, flumazenil and hydroxyzine) as well as therapy. While the individual drugs had been approved by the FDA, their off-label use for addiction treatment has not. [2] Gabasync was marketed by Hythiam, Inc. which is owned by Terren Peizer, a former junk bond salesman who has since been indicted for securities fraud relative to another company. [3] [4] Hythiam has sought to patent the protocol and charges up to $15,000 per patient to license its use (of which half goes to the prescribing physician, and half to Hythiam). [5] Lower rates are offered to the criminal justice system, where it has been used in drug court pilot programs. [6]

Contents

In November 2011, the results of a double-blind, placebo-controlled study (financed by Hythiam and carried out at UCLA) were published in the peer-reviewed journal Addiction . It concluded that Gabasync is ineffective: "The PROMETA protocol, consisting of flumazenil, gabapentin and hydroxyzine, appears to be no more effective than placebo in reducing methamphetamine use, retaining patients in treatment or reducing methamphetamine craving." [7]

History

In 2004 Terren Peizer, a former junk bond salesman, founded Hythiam Inc., a tiny pharmaceutical company, from which in 2006 when he was majority shareholder he received $1.3 million in compensation. [8] [9] [10] The firm bought the rights to an ineffective addiction treatment, and marketed it. [11] Despite the fact that no placebo-controlled or double-blind study or peer-reviewed publication of its "Prometa" (the marketing name for Gabasync) approach had been undertaken, and although no FDA approval had been obtained, Hythiam advertised the "innovative, medically based treatment" (which could cost $15,000 per patient) and franchised doctors to use Prometa, in exchange for a per-patient fee. [12] [9] Barrons , in a November 2005 article entitled "Curb Your Cravings For This Stock", wrote "If the venture works out for patients and the investing public, it'll be a rare success for Peizer, who's promoted a series of disappointing small-cap medical or technology stocks ... since his days at Drexel". [9] Peizer said: "Hythiam is my biggest triumph. If it's the only thing I did, then my life would have been a tremendous success." [13]

Journalist Scott Pelley said to Peizer in 2007: "Depending and who you talk to, you're either a revolutionary or a snake oil salesman." [12] 60 Minutes , NBC News , and The Dallas Morning News criticized Peizer after the company bypassed clinical studies and government approval when bringing to market Prometa; the addiction drug proved to be completely ineffective. [14] [15] [1] [16] Journalist Adam Feuerstein opined: "most of what Peizer says is dubious-sounding hype". [17] In June 2008, Hythiam had generated a net loss each year for 5 straight years, and while its stock had traded at $61.26 a share in 2007, it traded at $0.18 per share three years later. [18] [19] According to independent investment research firm Morningstar: "Over the long haul, this company has posted some of its industry's worst returns on assets." [18]

Treatment steps

For alcohol dependence, the treatment consists of flumazenil (administered intravenously), hydroxyzine, and gabapentin. The treatment is similar for stimulant dependence, with additional flumazenil administrations. The dosing regimen of the drug combination is discussed in Urschel’s study. The initial intravenous administrations are followed up by orally prescribed medications and behavioral treatment. [20]

Controlled studies

Preliminary evidence that a regimen combining hydroxyzine, flumazenil, and gabapentin (the active pharmacological components of Gabasync) can help decrease methamphetamine cravings and use was first published in October 2007 following a relatively small, open-label trial by Dr. Harold C. Urschel. The study, funded by Hythiam, was published in the Mayo Clinic Proceedings, a peer reviewed medical journal. [20]

60 Minutes reported that Dr. Urschel's addiction clinic sold the Gabasync treatment. However Urschel denied this was a conflict of interest. [1]

Dr. Urschel has also completed a double-blind, placebo controlled study of Gabasync's active ingredients, where 68 patients were randomized to active and 67 patients to placebo treatment for 30 days. The study reported a decrease in both cravings and methamphetamine use following the initial treatment and throughout the 30 days treatment period. [21]

The effects of the flumazenil/gabapentin combination in the treatment of alcohol dependence are less clear. In a randomized, placebo-controlled trial alcohol-dependent subjects taking flumazenil/gabapentin had more abstinent days and time to first heavy drinking if they had high alcohol withdrawal symptoms prior to treatment, whereas the patients with low withdrawal symptoms actually did worse with active treatment. [22]

Pilot programs

A Hythiam press release in 2004 announced that a center in Covington, Louisiana, would offer the treatment that was to become known as Gabasync in that court's drug program. However, the program was never implemented, and the judge there said he was uncomfortable that the evidence for it was not as strong as the company's marketing. As a result, the first Gabasync pilot took place in Gary, Indiana, beginning in November 2005. According to Hythiam the trial was a success and had been adopted, but, according to the Tahoma audit, it was ended early and not adopted. [23] [24] Karen Freeman-Wilson, who had been promoting the Gabasync trial as the CEO of National Association of Drug Court Professionals, later joined the Board of Directors at Hythiam. [25]

Another trial in Fulton County, Georgia, ended early because it was not deemed effective; one report mentioned physician misconduct, but court officials would not comment about the issue. [26] [24]

Pierce County, Washington, initiated a 40-person pilot program in 2006 through a nonprofit treatment center serving the county's drug court, and officials reported very promising results. [27] With this they were able to get $900,000 for Gabasync funding in the state and county budgets for 2007, including a University of Washington study to evaluate the treatment. However, it was subsequently revealed that county executive John Ladenburg, state legislator Dennis Flannigan, and officials at the treatment center had bought Hythiam stock. [1] [28] A county audit also questioned the effectiveness of the program, in part because auditors took a different approach than the treatment center in determining whether Gabasync was successful. [24] [29]

These revelations led the Pierce County Council to suspend its funding for the program in October 2007. [30] An unspent $175,000, along with $400,000 Ladenburg had requested for 2008, were instead set aside with the proviso that they could be used for "evidence-based programs that are directed towards breaking the cycle of drug addiction". [31] Ladenburg and Flannigan also had to amend their state financial disclosure forms, although Ladenburg reported he had sold his stock at a loss and insisted it did not influence his actions. [32] The news from Pierce County, along with a 60 Minutes investigation of Gabasync that aired in December, battered Hythiam's stock, as it fell in value nearly two-thirds by the end of the year. [26] However, at the same time the city council in nearby Federal Way, Washington, approved a small $20,000 Gabasync trial at the suggestion of a city council member whose employee, one of Gabasync's successes, had been treated in Pierce County and featured in the 60 Minutes report. [33]

Also in 2007, Jerry Madden, chair of the Texas House Corrections Committee, secured $2 million of funding over two years in the state budget for Gabasync treatment programs. In contrast with officials in Washington, Madden said he had no financial ties to Hythiam. In support of the budget request he cited a 20-person pilot paid for by Hythiam in Collin County, where the local judge, Charles Sandoval, reported a "spectacular" success rate (even though, when asked, stated that he hadn't kept any records). [34] [35] Other courts in the state were more skeptical about the lack of clinical research supporting Gabasync, however, and only four other counties requested funding. About half of the amount budgeted for the initial year was spent. [16]

Despite a ban on marketing of off-label drug use, Hythiam started a national advertising campaign in 2006, utilizing billboards, radio spots, as well as Internet ads and paid search results. [36] [37] In one of the billboard ads the image of Chris Farley (who had died of a drug overdose) was used, which caused significant controversy. [38] [39] Ads with other dead celebrities were planned (according to Hythiam's CEO, Terren Peizer, who has since been indicted for securities fraud relative to another company), but it seems none were actually published. [40] [3]

Actress Lindsay Lohan was connected to Gabasync as one of her rehab efforts during 2007, when Star Magazine reported that she was being treated by Dr. Matthew Torrington, director of the Gabasync Center in Santa Monica. [41] Gabasync was also featured in an episode of the MTV series True Life , in which recovering methamphetamine addict "Dustin" allowed the network to film his treatment with Gabasync, as well as his life before and after he quit using the drug. [42]

Related Research Articles

<span class="mw-page-title-main">Drug rehabilitation</span> Processes of treatment for drug dependency

Drug rehabilitation is the process of medical or psychotherapeutic treatment for dependency on psychoactive substances such as alcohol, prescription drugs, and street drugs such as cannabis, cocaine, heroin, and amphetamines. The general intent is to enable the patient to confront substance dependence, if present, and stop substance misuse to avoid the psychological, legal, financial, social, and medical consequences that can be caused.

<span class="mw-page-title-main">Gabapentin</span> Anticonvulsant medication

Gabapentin, sold under the brand name Neurontin among others, is an anticonvulsant medication primarily used to treat partial seizures and neuropathic pain. It is a commonly used medication for the treatment of neuropathic pain caused by diabetic neuropathy, postherpetic neuralgia, and central pain. It is moderately effective: about 30–40% of those given gabapentin for diabetic neuropathy or postherpetic neuralgia have a meaningful benefit.

<span class="mw-page-title-main">Opioid use disorder</span> Medical condition

Opioid use disorder (OUD) is a substance use disorder characterized by cravings for opioids, continued use despite physical and/or psychological deterioration, increased tolerance with use, and withdrawal symptoms after discontinuing opioids. This disorder is much more prevalent than first realized. Opioid withdrawal symptoms include nausea, muscle aches, diarrhea, trouble sleeping, agitation, and a low mood. Addiction and dependence are important components of opioid use disorder.

<span class="mw-page-title-main">Flumazenil</span> GABA receptor antagonist drug and benzodiazepine antidote

Flumazenil is a selective GABAA receptor antagonist administered via injection, otic insertion, or intranasally. Therapeutically, it acts as both an antagonist and antidote to benzodiazepines, through competitive inhibition.

<span class="mw-page-title-main">Naltrexone</span> Medication

Naltrexone, sold under the brand name Revia among others, is a medication primarily used to manage alcohol use or opioid use disorder by reducing cravings and feelings of euphoria associated with substance use disorder. It has also been found effective in the treatment of other addictions and may be used for them off-label. An opioid-dependent person should not receive naltrexone before detoxification. It is taken orally or by injection into a muscle. Effects begin within 30 minutes, though a decreased desire for opioids may take a few weeks to occur.

Substance dependence, also known as drug dependence, is a biopsychological situation whereby an individual's functionality is dependent on the necessitated re-consumption of a psychoactive substance because of an adaptive state that has developed within the individual from psychoactive substance consumption that results in the experience of withdrawal and that necessitates the re-consumption of the drug. A drug addiction, a distinct concept from substance dependence, is defined as compulsive, out-of-control drug use, despite negative consequences. An addictive drug is a drug which is both rewarding and reinforcing. ΔFosB, a gene transcription factor, is now known to be a critical component and common factor in the development of virtually all forms of behavioral and drug addictions, but not dependence.

NicVAX is an experimental conjugate vaccine intended to reduce or eliminate physical dependence to nicotine. According to the U.S. National Institute of Drug Abuse, NicVAX can potentially be used to inoculate against nicotine addiction. This proprietary vaccine is being developed by Nabi Biopharmaceuticals of Rockville, MD. with the support from the U.S. National Institute on Drug Abuse. NicVAX consists of the hapten 3'-aminomethylnicotine which has been conjugated (attached) to Pseudomonas aeruginosa exotoxin A.

<span class="mw-page-title-main">Benzodiazepine withdrawal syndrome</span> Signs and symptoms due to benzodiazepine discontinuation in physically dependent persons

Benzodiazepine withdrawal syndrome is the cluster of signs and symptoms that may emerge when a person who has been taking benzodiazepines as prescribed develops a physical dependence on them and then reduces the dose or stops taking them without a safe taper schedule.

Post-acute withdrawal syndrome (PAWS) is a hypothesized set of persistent impairments that occur after withdrawal from alcohol, opiates, benzodiazepines, antidepressants, and other substances. Infants born to mothers who used substances of dependence during pregnancy may also experience a PAWS. While PAWS has been frequently reported by those withdrawing from opiate and alcohol dependence, the research has limitations. Protracted benzodiazepine withdrawal has been observed to occur in some individuals prescribed benzodiazepines.

<span class="mw-page-title-main">Alcohol withdrawal syndrome</span> Medical condition

Alcohol withdrawal syndrome (AWS) is a set of symptoms that can occur following a reduction in alcohol use after a period of excessive use. Symptoms typically include anxiety, shakiness, sweating, vomiting, fast heart rate, and a mild fever. More severe symptoms may include seizures, and delirium tremens (DTs); which can be fatal in untreated patients. Symptoms start at around 6 hours after last drink. Peak incidence of seizures occurs at 24-36 hours and peak incidence of delirium tremens is at 48-72 hours.

<span class="mw-page-title-main">Polysubstance dependence</span> A type of substance use disorder

Polysubstance dependence refers to a type of substance use disorder in which an individual uses at least three different classes of substances indiscriminately and does not have a favorite substance that qualifies for dependence on its own. Although any combination of three substances can be used, studies have shown that alcohol is commonly used with another substance. One study on polysubstance use categorized participants who used multiple substances according to their substance of preference. The results of a longitudinal study on substance use led the researchers to observe that excessively using or relying on one substance increased the probability of excessively using or relying on another substance.

<span class="mw-page-title-main">Karen Freeman-Wilson</span> American mayor (born 1960)

Karen Marie Freeman-Wilson is an American attorney, former judge, and politician who served as Indiana Attorney General from 2000 to 2001, as well as mayor of Gary, Indiana from 2012 to 2019. She has been President and CEO of the Chicago Urban League since January 2020.

Olivier Ameisen was a French-American cardiologist who wrote a best-selling book about curing alcoholism using the drug baclofen.

<span class="mw-page-title-main">Benzodiazepine dependence</span> Medical condition

Benzodiazepine dependence defines a situation in which one has developed one or more of either tolerance, withdrawal symptoms, drug seeking behaviors, such as continued use despite harmful effects, and maladaptive pattern of substance use, according to the DSM-IV. In the case of benzodiazepine dependence, the continued use seems to be typically associated with the avoidance of unpleasant withdrawal reaction rather than with the pleasurable effects of the drug. Benzodiazepine dependence develops with long-term use, even at low therapeutic doses, often without the described drug seeking behavior and tolerance.

<span class="mw-page-title-main">Cannabis use disorder</span> Continued use of cannabis despite clinically significant impairment

Cannabis use disorder (CUD), also known as cannabis addiction or marijuana addiction, is a psychiatric disorder defined in the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and ICD-10 as the continued use of cannabis despite clinically significant impairment.

The National Association of Drug Court Professionals (NADCP) is the former name of All Rise, an American 501(c)(3) non-profit organization devoted to furthering the treatment court model and criminal justice reform worldwide. In 2023, NADCP announced it was rebranding to All Rise.

Terren Scott Peizer is an American businessperson. On June 21, 2024, he was found guilty by a California federal jury of three counts of insider trading and securities fraud, following a nine-day trial. Peizer faces a maximum penalty of 65 years in prison.

Discrimination against people with substance use disorders is a form of discrimination against people with this disease. In the United States, people with substance use disorders are often blamed for their disease, which is often seen as a moral failing, due to a lack of public understanding about substance use disorders being diseases of the brain with 40-60% heritability. People with substance use disorders are likely to be stigmatized, whether in society or healthcare.

<span class="mw-page-title-main">Prescription drug addiction</span> Medical condition

Prescription drug addiction is the chronic, repeated use of a prescription drug in ways other than prescribed for, including using someone else’s prescription. A prescription drug is a pharmaceutical drug that may not be dispensed without a legal medical prescription. Drugs in this category are supervised due to their potential for misuse and substance use disorder. The classes of medications most commonly abused are opioids, central nervous system (CNS) depressants and central nervous stimulants. In particular, prescription opioid is most commonly abused in the form of prescription analgesics.

<span class="mw-page-title-main">Joseph R. Volpicelli</span> American psychiatrist

Joseph R. Volpicelli is an American psychiatrist, research scientist, medical academic, and expert in the treatment of addictive disorders. He is professor emeritus, Perelman School of Medicine at the University of Pennsylvania. He is board certified in neurology, psychiatry and addiction psychiatry. He currently is medical director at Volpicelli Center, an out-patient addiction treatment facility in Plymouth Meeting, Pennsylvania, as well as the executive director at Institute of Addiction Medicine, a non-profit research entity also in Plymouth Meeting, Pennsylvania.

References

  1. 1 2 3 4 "Prescription For Addiction". 60 Minutes. CBS News. December 9, 2007. Retrieved 2008-08-22.
  2. ↑ Prometa Founder's Spotty Background Explored, November 3, 2006, http://www.drugfree.org/join-together/prometa-founders-spotty-background-explored/ Archived 2015-09-23 at the Wayback Machine
  3. 1 2 "UNITED STATES V. TERREN S. PEIZER". www.justice.gov. March 1, 2023.
  4. ↑ Prescription For Addiction, 60 Minutes' Scott Pelley Reports On A New Addiction Treatment, Dec. 7, 2007, http://www.cbsnews.com/news/prescription-for-addiction/
  5. ↑ "Prometa under fire in Washington drug court program". Alcoholism & Drug Abuse Weekly. 20 (3). January 21, 2008. doi:10.1002/adaw.20121.
  6. ↑ Roan, Shari (October 9, 2006). "Addiction treatment, novel but unproved; Prometa's promoters point to anecdotal success. But critics want to see hard numbers". Los Angeles Times. p. F1.
  7. ↑ Ling, W.; Shoptaw, S.; Hillhouse, M.; Bholat, M. A. (November 2011). "Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence". Addiction. 107 (2): 361–369. doi:10.1111/j.1360-0443.2011.03619.x. PMC   4122522 . PMID   22082089.
  8. ↑ "Hythiam EVP Lamacchia in long string of company layoffs". Treatment Magazine. November 21, 2019. Archived from the original on November 21, 2019. Retrieved April 5, 2023.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  9. 1 2 3 Alpert, Bill (November 7, 2005). "Curb Your Cravings For This Stock". The Wall Street Journal.
  10. ↑ Bartholomew, Dana (7 December 2018). "Catasys Thrives on Data Dives". Los Angeles Business Journal. Retrieved 12 August 2020.
  11. ↑ Alpert, Bill. "Curb Your Cravings For This Stock". Barrons. Retrieved 2020-11-26.
  12. 1 2 "Prescription For Addiction". CBS News. December 7, 2007.
  13. ↑ Polien Light, Nina (May 8, 2008). "An entrepreneur with heart". Cleveland Jewish News. Retrieved February 6, 2022.
  14. ↑ Kari Huus (February 5, 2007). "Unproven meth, cocaine 'remedy' hits market". NBC News.
  15. ↑ Humphreys, Keith (January 24, 2012). "The Rise and Fall of a "Miracle Cure" for Drug Addiction". Washington Monthly.
  16. 1 2 Ramshaw, Emily (January 20, 2008). "Texas' Prometa program for treating meth addicts draws skeptics". Dallas Morning News. Archived from the original on 2010-10-27.
  17. ↑ Adam Feuerstein (November 13, 2007). "Biotech Notebook: Hythiam, Shire, Genentech; Talk is proving cheap at Hythiam," TheStreet.
  18. 1 2 "Junk Bonds to Junk Science? Drug Treatment Program Questioned". Prison Legal News. June 15, 2008.
  19. ↑ "Hythiam stock price".
  20. 1 2 Urschel 3rd, Harold C; Hanselka, Larry L; Gromov, Irin; White, Lenae; Baron, Michael (2007). "Open-label study of a proprietary treatment program targeting type A gamma-aminobutyric acid receptor dysregulation in methamphetamine dependence". Mayo Clin. Proc. 82 (10): 1170–8. doi:10.4065/82.10.1170. PMID   17908523.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  21. ↑ Urschel, HC; Hanselka, LL; Baron, M (November 2009). "A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence". J. Psychopharmacol. (Oxford). 25 (2): 254–62. doi:10.1177/0269881109349837. PMID   19939864. S2CID   34039260.
  22. ↑ Anton, RF; Myrick, H; Baros, AM; et al. (August 2009). "Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms". J Clin Psychopharmacol. 29 (4): 334–42. doi:10.1097/JCP.0b013e3181aba6a4. PMID   19593171. S2CID   27738868.
  23. ↑ "PROMETA Protocol Adopted by Gary, Indiana". businesswire.com (Press release).
  24. 1 2 3 "Effectiveness of Prometa Treatment Protocol in Pierce County Drug Courts". Pierce County Performance Audit Committee.
  25. ↑ "Hythiam, Inc. Appoints Past Indiana State Attorney General and Former Head of National Drug Court Institute to Board of Directors". biospace.com. 10 July 2007.
  26. 1 2 Robinson, Sean (December 23, 2007). "Data show mixed value of Prometa". The News Tribune.
  27. ↑ Clarridge, Christine (July 9, 2006). "Pilot program helps ease drug addictions". Seattle Times. Retrieved 2008-08-25.
  28. ↑ Otto, M. Alexander (October 24, 2007). "Local officials owned stock in company". The News Tribune. p. 106.
  29. ↑ Robinson, Sean (November 11, 2007). "Success or failure? Probing Prometa" (PDF). The News Tribune.
  30. ↑ Otto, M. Alexander (October 24, 2007). "Council cuts off drug program" (PDF). The News Tribune.
  31. ↑ Wickert, David (November 21, 2007). "Council rejects Prometa funding request". The News Tribune.
  32. ↑ Wickert, David (November 6, 2007). "Politicians revise stock disclosures". The News Tribune.
  33. ↑ Maynard, Steve (November 22, 2007). "In Federal Way, Prometa gets council support". The News Tribune.
  34. ↑ "Junk Bonds to Junk Science? Drug Treatment Program Questioned". prisonlegalnews.org.
  35. ↑ "The Worst Judge in Dallas County". dmagazine.com. 18 November 2009.
  36. ↑ "Actor who died of overdose stars in addiction treatment ads". adage.com.
  37. ↑ "A warning sign on Sunset". Los Angeles Times. 6 April 2006.
  38. ↑ "Addiction treatment's effectiveness argued". The Seattle Times.
  39. ↑ "Billboard in Los Angeles". jugularnyc.com.
  40. ↑ "Chris Farley Lives on Billboard". eonline.com. 3 April 2006.
  41. ↑ "Lindsay's Shocking Drug Therapy". Star Magazine. October 24, 2007. Retrieved 2008-08-22.
  42. ↑ "I'm Going to Rehab". True Life. MTV. December 6, 2007. Archived from the original (video) on 2007-12-13. Retrieved 2007-12-10.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.